hVIVO plc (AIM & Euronext: HVO) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces
hVIVO plc (AIM & Euronext: HVO) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces
hVIVO saw record revenues for another year in 2022 as demand for its human challenge trials accelerated. And 2023 could see further gains.
EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth
€3.2m contract for Venn Life Sciences with global pharmaceutical client
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
Early data readout indicates a successful LPS human challenge trial
£5.2m RSV human challenge study contract with global biotechnology company in Asia Pacific and Notice of Trading Update
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
Cathal Friel’s latest venture, Poolbeg Pharma, a clinical-stage infectious disease firm spun out of Open Orphan, aims to tap into the almost €200 billion infectious disease market.
Phase I results for Imutex’s mosquito vaccine candidate published in leading peer-reviewed journal
Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases